Long‐term follow‐up of 64 children with classical infantile‐onset Pompe disease since 2004: A French real‐life observational study

Background Classical infantile‐onset Pompe disease (IOPD) is the most severe form of Pompe disease. Enzyme replacement therapy (ERT) has significantly increased survival but only a few studies have reported long‐term outcomes. Methods We retrospectively analyzed the outcomes of classical IOPD patien...

Full description

Saved in:
Bibliographic Details
Published in:European journal of neurology 2023-09, Vol.30 (9), p.2828-2837
Main Authors: Tardieu, Marine, Cudejko, Céline, Cano, Aline, Hoebeke, Célia, Bernoux, Delphine, Goetz, Violette, Pichard, Samia, Brassier, Anaïs, Schiff, Manuel, Feillet, François, Rollier, Paul, Mention, Karine, Dobbelaere, Dries, Fouilhoux, Alain, Espil‐Taris, Caroline, Eyer, Didier, Huet, Frédéric, Walther‐Louvier, Ulrike, Barth, Magalie, Chevret, Laurent, Kuster, Alice, Lefranc, Jérémie, Neveu, Julien, Pitelet, Gaele, Ropars, Juliette, Rivier, François, Roubertie, Agathe, Touati, Guy, Vanhulle, Catherine, Tardieu, Emilie, Caillaud, Catherine, Froissart, Roseline, Champeaux, Murielle, Labarthe, François, Chabrol, Brigitte
Format: Article
Language:English
Subjects:
Age
Antibodies
Cardiomyopathy
Congestive heart failure
Effectiveness
enzyme replacement therapy
Hypotonia
Immunomodulation
infantile‐onset Pompe disease
Life Sciences
long‐term outcomes
Morbidity
Mortality
Observational studies
Pathogenesis
Pulmonary functions
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Classical infantile‐onset Pompe disease (IOPD) is the most severe form of Pompe disease. Enzyme replacement therapy (ERT) has significantly increased survival but only a few studies have reported long‐term outcomes. Methods We retrospectively analyzed the outcomes of classical IOPD patients diagnosed in France between 2004 and 2020. Results Sixty‐four patients were identified. At diagnosis (median age 4 months) all patients had cardiomyopathy and most had severe hypotonia (57 of 62 patients, 92%). ERT was initiated in 50 (78%) patients and stopped later due to being ineffective in 10 (21%). Thirty‐seven (58%) patients died during follow‐up, including all untreated and discontinued ERT patients, and 13 additional patients. Mortality was higher during the first 3 years of life and after the age of 12 years. Persistence of cardiomyopathy during follow‐up and/or the presence of heart failure were highly associated with an increased risk of death. In contrast, cross‐reactive immunologic material (CRIM)‐negative status (n = 16, 26%) was unrelated to increased mortality, presumably because immunomodulation protocols prevent the emergence of high antibody titers to ERT. Besides survival, decreased ERT efficacy appeared after the age of 6 years, with a progressive decline in motor and pulmonary functions for most survivors. Conclusions This study reports the long‐term follow‐up of one of the largest cohorts of classical IOPD patients and demonstrates high long‐term mortality and morbidity rates with a secondary decline in muscular and respiratory functions. This decreased efficacy seems to be multifactorial, highlighting the importance of developing new therapeutic approaches targeting various aspects of pathogenesis.
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.15894